CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID...
Phase 2
Oak Forest, Illinois, United States and 12 other locations
a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =\<2500 U/mL SARS-CoV-2 S antibody concentr...
Phase 2
Chicago, Illinois, United States and 5 other locations
in treating high-risk participants who have tested positive for Covid-19. The main question\[s\] it aims to answer are:* To evaluat-...
Phase 2
Berwyn, Illinois, United States and 3 other locations
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or...
Phase 3
Oak Brook, Illinois, United States and 17 other locations
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...
Phase 3
Chicago, Illinois, United States of America and 217 other locations
This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI--...
Phase 2
Chicago, Illinois, United States and 54 other locations
(SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID...
Phase 2
Chicago, Illinois, United States and 144 other locations
This is an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 g...
Phase 1
Chicago, Illinois, United States and 16 other locations
known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...
Phase 2, Phase 3
Chicago, Illinois, United States and 214 other locations
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination agai...
Phase 1
Chicago, Illinois, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal